title: A Dengue Vaccine.
abstract: Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year.
authors.affiliation: Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. Electronic address: adurbin1@jhu.edu.
authors.forename: Anna P
authors.initials: AP
authors.lastname: Durbin
mesh_terms: D004274:DNA, Recombinant / Q000008:administration & dosage / Q000276:immunology; D003715:Dengue / Q000276:immunology / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans
chemical_list: D004274:DNA, Recombinant; D053059:Dengue Vaccines